β-微管蛋白的表达对胃癌根治术后辅助化疗的影响及其与预后的关系  

Influence of β-tubulin mRNA expression on post-gastrectomy paclitaxel chemotherapy and prognosis of gastric cancer

作　　者：张占东[1] 马飞[1] 张永磊[1] 马二民[2] 孔烨[1] 刘洪兴[1] 花亚伟[1] 

机构地区：[1]河南省肿瘤医院普通外科,河南郑州450003 [2]河南省郑州市第五人民医院肿瘤外科,河南郑州450003

出　　处：《中国普通外科杂志》2013年第4期418-422,共5页China Journal of General Surgery

摘　　要：目的:探讨胃癌患者胃癌组织中β-微管蛋白表达水平对胃癌根治术后紫杉醇化疗效果的影响。方法:选择接受胃癌根治术并术后进行紫杉醇辅助化疗的332例胃癌患者的组织样本,采用RT-PCR法检测β-微管蛋白的mRNA表达水平,分析患者临床特征与β-微管蛋白mRNA表达的关系;Kaplan-Meier法比较β-微管蛋白高、低表达组生存时间的差异。结果:β-微管蛋白的mRNA表达水平与患者年龄、性别、肿瘤部位和肿瘤大小均无明显关系(均P>0.05),而与分化程度、TNM分期、淋巴结转移和远处转移有关(均P<0.05);β-微管蛋白的mRNA高表达组患者的术后生存时间比低表达组患者术后生存时间短,差异有统计学意义(P<0.05)。结论:胃癌组织中的β-微管蛋白表达水平与胃癌根治术及术后紫杉醇辅助化疗患者的远期生存率有密切关系,可作为患者预后的判断指标。Objective： To investigate the influence of β-tubulin expression level in cancer tissues of gastric cancer patients on the efficacy ofpaclitaxel chemotherapy after radical gastrectomy. Methods： Cancer tissues from 332 patients with stomach cancer undergoing post-gastrectomy paclitaxel chemotherapy were collected. The β-tubulin mRNA expression in the cancer tissues was measured by RT-PCR, and then the relations of β-tubulin mRNA expression with the clinical characteristics of the patients were analyzed. In addition, the survival difference between two groups of patients with high and low β-tubulin expression was compared by Kaplan-Meier method. Results： β-tubulin mRNA expression in gastric cancer was unrelated to the age or gender of the patients, or the location and size of the tumors （all P〉0.05）, but was associated with the degree of differentiation, TNM stage, and lymphatic and distant metastasis （all P〈0.05）. q-he survival time of patients from high β-tubulin expression group was significantly shorter than that from low β-tubulin expression group （P〈0.05）. Conclusion： β-tubulin expression level in gastric cancer is closely related to the long-term survival of gastric cancer patients undergoing post-gastrectomy paclitaxel chemotherap）5 and can be used as predictive index of prognosis.

关 键 词：胃肿瘤 病理学 紫杉酚 微管蛋白 预后 

分 类 号：R735.2[医药卫生—肿瘤]